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miR-296-5pThere is a wide range of drugs and combinations under investigation and/or approved over the last decade to
treat colorectal cancer (CRC), but the 5-year survival rate remains poor at stages II–IV. Therefore, new, more-
efﬁcient drugs still need to be developed that will hopefully be included in ﬁrst-line therapy or overcome
resistance when it appears, as part of second- or third-line treatments in the near future. In this study, we
revealed that heat shock protein 90 (Hsp90) inhibitors have high therapeutic potential in CRC according to
combinative analysis of NCBI's Gene Expression Omnibus (GEO) repository and chemical genomic database of
Connectivity Map (CMap). We found that second generation Hsp90 inhibitor, NVP-AUY922, signiﬁcantly down-
regulated the activities of a broad spectrumof kinases involved in regulating cell growth arrest and death of NVP-
AUY922-sensitive CRC cells. To overcome NVP-AUY922-induced upregulation of survivin expression which
causes drug insensitivity,we found that combining berberine (BBR), a herbalmedicinewith potency in inhibiting
survivin expression, with NVP-AUY922 resulted in synergistic antiproliferative effects for NVP-AUY922-sensitive
and -insensitive CRC cells. Furthermore, we demonstrated that treatment of NVP-AUY922-insensitive CRC cells
with the combination of NVP-AUY922 and BBR caused cell growth arrest through inhibiting CDK4 expression
and induction of microRNA-296-5p (miR-296-5p)-mediated suppression of Pin1–β-catenin–cyclin D1 signaling
pathway. Finally, we found that the expression level of Hsp90 in tumor tissues of CRC was positively correlated
with CDK4 and Pin1 expression levels. Taken together, these results indicate that combination of NVP-AUY922
and BBR therapy can inhibit multiple oncogenic signaling pathways of CRC.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) is the third most common cancer, and the
third leading cause of cancer deaths inWestern countries [1]. The choice
for treating early rectal cancer is complete local excision [2]. Although
surgery is reported to cure approximately 50% of patients with CRC
[3], approximately 40% of patients who undergo the ﬁrst curative
surgery present with suspected recurrence in the initial 2 years ofe no conﬂicts of interest.
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ical University, 250 Wu-Hsing
7; fax: +886 2 66387537.follow-up [1]. In addition, approximately 50–70% of patients with CRC
are diagnosed at more-advanced stages [4]. For these patients with
CRC at stages II and III, in addition to the surgical resection, adjuvant
postoperative chemotherapy may provide an additional beneﬁt by
eradicating potentially existing micrometastases and reduce the risk of
cancer relapse after surgery [2].
Drug treatment for CRC has transitioned from single-agent chemo-
therapy to combination cytotoxic therapies and target-speciﬁc agents
[5], but the 5-year survival rate remains poor at stages II–IV despite
recent advances in chemotherapy and targeted agents. Clearly, better
and more-efﬁcacious drugs are needed, and target-speciﬁc agents
remain the future of cancer treatment.
Drugs that are most commonly used to treat advanced and
metastatic CRC are ﬂuorouracil (5-FU), capecitabine, irinotecan and
oxaliplatin. These four compounds are the bases of standard treatments
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adjuvant 5-FU for 6 months reduces the risk of death by 30% [6]. But,
in the XELOXA study of oral capecitabine plus oxaliplatin versus 5-FU
and folinic acid (for stage III disease), there was an insigniﬁcant 5-year
beneﬁt in overall survival [7]. These data and toxicity considerations
imply that new drugs and new regimens are expected to improve the
response of CRC to pharmacological treatments.
Gene expression proﬁling is used as a powerful tool for elucidating
disease-speciﬁc molecular mechanisms and biological pathways [8],
predicting drug responses and resistance [9] and disease outcomes
[10], and discovering new targets [2]. Several studies used gene expres-
sion proﬁles of CRC tissues to predict a poor prognosis and determine
patients at high risk of recurrence [11,12]. There is yet no comprehen-
sive CRC gene expression of a related application system that specializes
in anticancer agents. A novel technique to discover potentially
therapeutic chemicals through a collection of chemically induced gene
expression proﬁles, the Connectivity Map (CMap), proposed by Lamb
et al. [13,14], and recently validated by Sirota et al. [15], demonstrated
how integrating genome-wide gene expression data of drugs and
diseases can be used for compound repositioning. Hence, the combina-
tion of a genome-wide expression database of CRC and chemical
genomic database can identify potential therapeutic agents for CRC. In
this study, we analyzed the genomic signature of human CRC tissues
to ﬁnd very strong positive connections with heat shock protein 90
(Hsp90) inhibitors for treating CRC. We demonstrated that the second
generation Hsp90 inhibitor, NVP-AUY922, is a potent apoptosis inducer
in CRC cell lines. Furthermore, we found that its combination with a
traditional herbal medicine, berberine (BBR), inhibited NVP-AUY922-
induced drug resistance of CRC cells.
2. Materials and methods
2.1. Chemicals, reagents, antibodies and expression construct
The drug 17-allylamino-demethoxy geldanamycin (17-AAG) and
berberine (BBR) were purchased from Sigma (St. Louis, MO, USA). NVP-
AUY922 was purchased from Selleck Chemicals LLC (Houston, TX, USA).
These three compounds were prepared in 100% DMSO. Crystal violet,
propidium iodide (PI), and DMSO were all obtained from Sigma (St.
Louis, MO, USA). Small interfering (si)RNA targeting survivin messenger
(m)RNA, control siRNA, and the RNAiMax transfection reagent were
purchased from Invitrogen (Carlsbad, CA, USA). Rabbit antibodies against
Hsp90, HSF-1, survivin, CDK4, poly(ADP-ribose) polymerase (PARP),
Ser(P)2448-mTOR, mTOR, Thr(P)389-p70S6K, p70S6K, Ser(P)473-Akt,
Thr(P)308-Akt, Akt, Thr(P)183/Tyr(P)185-JNK, and JNK were obtained
from Cell Signaling (Beverly, MA, USA); cyclin D1 and GFP were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mousemonoclonal anti-
bodies against caspase-3 and β-actin were respectively purchased from
Imgenex (San Diego, CA, USA) and MP Biomedicals (Irvine, CA, USA).
The pEGFP-Pin1 expression vector was provided by Prof. Pei-Jung Lu.
2.2. Cell culture
CRC cell lines were provided by Prof. YW Cheng and Prof. H Lee's
laboratory. All CRC cell lineswere cultured inRPMI-1640, supplemented
with 10% fetal bovine serum (FBS) and antibiotics. CRL-1459/CCD-18Co
(non-malignant human colon cells)was providedby Prof. PJ Lu's labora-
tory and cultured inminimum essential Eagle's medium, supplemented
with 10% FBS and antibiotics.
2.3. Cell viability assay
Cell viability was determined by the crystal violet staining method,
as described previously [16]. In brief, cells were plated in 96-well dishes
at a density of 4000 cells/ml and were treated with DMSO, 17-AAG,
NVP-AUY922, BBR, or a combination of NVP-AUY922 and BBR at theindicated concentrations, and viable cells were stainedwith 0.5% crystal
violet in 30% ethanol for 10 min at room temperature for the indicated
time. Plates were then washed four times with tap water. After drying,
cells were lysed with a 0.1 M sodium citrate solution, and dye uptake
was measured at 550 nm using a 96-well plate reader. Cell viability
was calculated from the relative dye intensity compared to untreated
samples.2.4. Tissue microarray and CRC clinical specimens
A colon adenocarcinoma tissue array was purchased from US
Biomax (CO1505, including 50 cases of colon cancer tissues with
matched adjacent tissues as the controls). CRC tumor tissues were col-
lected from 192 nonselected patients who underwent surgical resection
for CRC at the Department of Surgery, Taipei Medical University Hospi-
tal (Taipei, Taiwan). All patients gave informed consent, and the proto-
col was approved by the IRB Committee before a tissue sample was
collected during their planned surgery. The clinical stages and patholog-
ic features of primary tumors were deﬁned according to the criteria of
the American Joint Commission on Cancer. All the tissue sections were
stained with a standard immunohistochemical (IHC) protocol. Brieﬂy,
slideswere deparafﬁnized by serial xylene–ethanol treatment. Antigens
were retrieved by boiling in sodium citrate buffer for 10 min. Slides
were blocked in 5% normal goat serum for 1 h at room temperature.
After blocking, slides were incubated with a primary antibody against
Hsp90, CDK4, survivin and Pin1, respectively, followed by a biotin-
conjugated secondary antibody, polymer-horseradish peroxidase
(HRP), and a diaminobenzidine tetrahydroxychloride (DAB) solution.
The intensity of staining was scored as follows: 0 point, negative; 1
point, weakly positive; 2 points, moderately positive; or 3 points,
strongly positive. The percentage of positive tumor cells (0–100%) was
multiplied by the intensity of all proteins staining; therefore, the overall
score ranged from 0 to 300. We divided the proteins expression scores
(0–300) into two groups: low expression (0–150) and high expression
(151–300).2.5. Quantitative reverse-transcription polymerase chain reaction (RT-
PCR)
Total RNA was extracted from the cell lines with or without drug
treatment using a Qiagen RNeasy kit and Qiashredder columns accord-
ing to the manufacturer's instructions (Qiagen, Valencia, CA, USA). One
microgram of total RNA was reverse-transcribed to complementary (c)
DNA using a ReactionReady™ First Strand cDNA Synthesis Kit
(SABiosciences, Frederick, MD, USA). A quantitative RT-PCRwas carried
out in an Applied Biosystems StepOnePlus™ Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) using an automated baseline
and threshold cycle detection. Sequences of speciﬁc primers for each
gene are listed in Supplementary Table 1. To detect the expression
level of miR-296-5p, ampliﬁcation and detection of speciﬁc products
were performed with the cycle proﬁle according to the miScript PCR
starter kit (Qiagen, Valencia, CA, USA). The relative gene expression
level was calculated by comparing the cycle times for each target PCR.
The target PCR Ct values were normalized by subtracting the internal
control of U6 rRNA Ct value.2.6. Cell-cycle analysis
Cells were treated with or without drugs for 48 h, and a cell-cycle
analysis was then performed. The distribution of cell-cycle phases was
assayed by PI staining and ﬂow cytometry (FACScan; BD Biosciences,
San Jose, CA, USA). Histogramswere ﬁt for cell-cycle ratios usingModFit
software (Verity Software, Turramurra, NSW, Australia).
Table 1
Top 10 ranked candidates for targeting colorectal cancer.
Rank Compound name Mean connection score No. of instances p Value
1 tanespimycin −0.808 62 0
2 LY-294002 −0.757 61 0
3 emetine −0.75 4 0.00046
4 apigenin −0.749 4 0.00084
5 medrysone −0.721 6 0.00085
6 apramycin −0.697 4 0.00101
7 cephaeline −0.692 5 0.00184
8 atracurium besilate −0.689 3 0.00238
9 atractyloside −0.688 5 0.00346
10 cefamandole −0.685 4 0.00354
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Cell lines were placed in lysis buffer at 4 °C for 1 h. Protein samples
were electrophoresed using 8–15% SDS-polyacrylamide gel electropho-
resis (PAGE) and performed as previously described [17].
2.8. Human phospho-kinase array
HCT-15 andHT-29 cell lineswere analyzed in the panel of phosphor-
ylation proﬁles of kinases after treatment with DMSO, NVP-AUY922
alone, and the combination of NVP-AUY922 and BBR (human
phospho-kinase array, ARY003; R&D Systems). This array speciﬁcally
screens for relative levels of phosphorylation of 42 individual proteins
involved in cellular proliferation and survival. After treatment with
DMSO, NVP-AUY922 alone (10 nM), and the combination of NVP-
AUY922 (10 nM) and BBR (10 μM), cell lysates were incubated with
the membrane. Thereafter, a cocktail of biotinylated detection antibod-
ies, streptavidin-HRP, and chemiluminescent detection reagents was
used to detect phosphorylated proteins. Relative expressions of speciﬁc
phosphorylated proteins were determined following quantiﬁcation of
scanned images by ImageJ compared to NVP-AUY922, the combination
of NVP-AUY922 and BBR, and the vehicle.
2.9. Connectivity Map (CMap) analysis
CMap (build02, http://www.broad.mit.edu/cmap/) contains more
than 7000 expression signatures representing 1309 compounds. Up-
and downregulated gene groups were simultaneously submitted to
CMap for analysis. Compounds with negative connectivity scores,
which imply a mode of action by the matched compounds to reverse
the expression direction of query genes in CRC, were recorded as poten-
tial therapeutic agents for CRC.
2.10. Statistical analyses
All observations were conﬁrmed by at least three independent
experiments. Results are presented as the mean ± SE. We used one-
tailed Student's t-tests for all comparison experiments. Survival curves
were analyzed using the log-rank Kaplan–Meier method. For drug
combination studies, the synergistic effect was assessed by the
combination index (CI), according to the method of Chou and Talalay
wherein synergism is deﬁned as CI b 1, while antagonism is CI N 1,
and an additive effect is considered to be CI = 1 [18]. CI values were
calculated using CompuSyn software (ComboSyn, Paramus, NJ, USA).
The correlation of levels of miR-296-5p and Pin1 was determined
using Pearson's test. A chi-square test was used to compare Hsp90,
CDK4, survivin and Pin1 protein expression with clinicopathologic
parameters. All statistical analyses were performed using SPSS software
(SPSS, Chicago, IL, USA).
3. Results
3.1. Hsp90 inhibitor with a high potential for treating CRC
Several studies used gene expression proﬁles of CRC tissues to predict
a poor prognosis anddetermine patients at high risk of recurrence [11,12].
But, there is no comprehensive clinical CRC gene expression proﬁling of a
related application system that specializes in anticancer agents. Hence,
we ﬁrst examined gene expression proﬁles of CRC patients using data ob-
tained from the GEO DataSet under accession number GSE21815. Gene
expression data of 132 samples of laser-microdissected CRC tumors and
nine normal colon controls of patients with no colorectal neoplasm
were retrieved from the GEO repository. Supplementary Table 2 summa-
rizes the characteristics of the clinical specimens of CRC used in the study.
To discover potentially therapeutic compounds through a combination of
chemically induced gene expression proﬁles and gene expression proﬁlesof CRC patients, we performed a CMap analysis.We speciﬁcally looked for
compounds that had a signature inversely correlated with the CRC-
speciﬁc signature, and the top 10 drugs identiﬁed by the CMap analysis
are summarized in Table 1. The ranking of candidate drugs was
established based on inverse connection scores and p values. At the top
of that list, the Hsp90 inhibitor, tanespimycin (17-AAG), showed signiﬁ-
cant negative enrichment. In addition, as shown in Supplementary
Fig. 1, the CMap analysis revealed that Hsp90 inhibitors, including
tanespimycin, geldanamycin, and alvespimycin, represent potential
candidates for treating CRC which suggested that Hsp90 may be a good
drug target for CRC.
3.2. Hsp90 is upregulated in colorectal tumors, and high Hsp90 expression
was correlated with a poor prognosis of patients with CRC
The molecular chaperone, Hsp90, plays important roles in the post-
translationalmaturation and activation ofmany critical oncogenic client
proteins, such as heat shock factor (HSF)-1 and survivin, which are
essential for facilitating malignant transformation and increasing the
survival, growth, and invasive potential of cancer cells [19]. To clarify
gene expression levels of Hsp90 and Hsp90 client proteins in CRC, we
analyzed Hsp90, HSF-1, and survivin gene expressions of 132 samples
of CRC tumors and nine normal colon controls of patients as mentioned
above. As shown in Fig. 1A, Hsp90 (left panel, p = 3.76E−17), HSF-1
(middle panel, p = 2.35E−16), and survivin (right panel, p =
7.75E−08) expression levels were signiﬁcantly upregulated in CRC
tumor tissues compared to the normal group. We further audited the
expression proﬁle of the Hsp90 protein in a colon adenocarcinoma
tissue array fromBioMax Company (Rockville, MD, USA) using standard
immunohistochemistry (IHC). Results revealed that Hsp90was upregu-
lated in representative images of three colon adenocarcinoma tissues
(Fig. 1B, left panel). Staining scores were obtained and deﬁned from
the immunoexpression of IHC (Supplementary Fig. 2) and indicated
that 37 (74%) CRC tissues exhibited strong positive staining (score
3) for Hsp90 (Fig. 1B, right panel), which indicates high expression of
the Hsp90 protein in CRC tissues compared to normal colorectal tissues.
To evaluate the prognostic signiﬁcance of Hsp90 expression, we
analyzed Hsp90 expression levels of CRC with outcomes was available
from the CRC Survival Metabase [20]. As shown in Fig. 1C, the expres-
sion level of Hsp90 was able to stratify patients by K-means clustering
into two subgroups (low- and high-risk groups) which exhibited
signiﬁcant differences (p= 0.0013) in CRC-speciﬁc survival according
to the Kaplan–Meier survival analysis (Fig. 1D). These results indicated
that Hsp90 expression was upregulated in CRC and was inversely
correlated with a CRC patient's prognosis.
3.3. The second generation Hsp90 inhibitor, NVP-AUY922, shows
therapeutic efﬁcacy in vitro in CRC cell lines
To evaluate the therapeutic efﬁcacy of anHsp90 inhibitor in CRC cell
lines, we ﬁrst assessed expression levels of Hsp90 and Hsp90 client pro-
teins at the mRNA and protein levels in CRC cell lines by a quantitative
Fig. 1. Hsp90 was upregulated in colorectal cancer (CRC) tumors and was associated with poor survival in patients with CRC. (A) High mRNA expression levels of HSP90, HSF-1, and
survivin were observed in the public mRNA dataset (GSE21815). (B) Left panel: Representative IHC images showHsp90 expression in paired normal tissues and tumors of three patients
with CRC. Right panel: Hsp90 protein expression levels obtained from the IHC results. The percentage of cases is indicated on the y-axis, whereas the type of sample is shown on the x-axis,
and the color indicates the Hsp90 expression score of from 0 to 3. (C) Box plots comparing differences in Hsp90 gene expression between risk groups using a t-test. (D) Accurately predict
patient outcomes using Kaplan–Meier analyses of patients with high expressions of Hsp90 (high risk) (n=398) from CRC Survival Metabase showing stratiﬁcation of Hsp90 for shorter-
surviving versus longer-surviving patients.
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titative RT-PCR primers used are listed in Supplementary Table 2. Com-
pared to non-cancerous human colon cells (CRL-1459), the Hsp90
mRNA (Fig. 2A) and protein (Fig. 2B) were highly expressed in CRC
cell lines, including HCT-15, HCT116WT, and DLD-1. Next, the high-
(HCT-15), middle-(HCT116WT), and low-(HT-29) Hsp90 protein-
expressing CRC cell lines were selected to determine the viability and
cytotoxicity of NVP-AUY922, which had higher potency and lower
toxicity than tanespimycin (17-AAG) [21]. Compared to untreated
cells, NVP-AUY922 exhibited strong antiproliferative effects in a dose-
dependent manner in both the HCT-15 and HCT116WT cell lines
(Fig. 2C, left and middle panels), and respective IC50 values of NVP-
AUY922 were 15.4 and 17.6 nM after 72 h of treatment. However, the
IC50 value of NVP-AUY922 was 49 nM in HT-29 cell line (Fig. 2C, right
panel). It has been demonstrated that NVP-AUY922 inhibits prolifera-
tion of various human cancer cell lines in vitro, with an average IC50
of 9 nM [22]. In addition, Ueno et al. [23] shown that lung cancer cells
with an IC50 of less than 50 nM of NVP-AUY922 were classiﬁed as
sensitive cells of lung cancer cell lines. Thus, these data suggest thatHT-29 cells are not sensitive to NVP-AUY922. We next conﬁrmed the
reduction in cell viability by a cell cycle analysis of the NVP-AUY922-
treated HCT-15 and HT-29 cell lines. We showed that treatment with
NVP-AUY922 at the indicated concentration for 48 h induced a marked
increase in the sub-G1 proportion of HCT-15 cells compared to the
control (p b 0.001), indicating the induction of cell death (Supplemen-
tary Fig. 3A). In contrast, the sub-G1 proportion of NVP-AUY922-treated
HT-29 cells was not affected (Supplementary Fig. 3B). We ﬁnally
analyzed the induction of apoptosis after NVP-AUY922 treatment in
the HCT-15, HCT116WT, and HT-29 cell lines using immunoblotting. It
was reported that CDK4 is a sensitive client protein to Hsp90 inhibitors
[24]. As shown in Fig. 2D, expression of CDK4was downregulated in the
NVP-AUY922-treated HCT-15 and HCT116WT cell lines. Moreover, NVP-
AUY922 increased apoptosis, as assessed by caspase-3 and poly-(ADP
ribose) polymerase (PARP) cleavage, in the HCT-15 and HCT116WT
cell lines. However, this phenomenon cannot be observed in HT-29
cells (Fig. 2D). Taken together, these data indicate that NVP-AUY922
had an antiproliferative effect by inducing apoptosis in the HCT-15
and HCT116WT cell lines.
Fig. 2. Cytotoxic effect of NVP-AUY922 in CRC cell lines. (A) The Hsp90, heat shock factor (HSF)-1, and survivin mRNA analyses were conducted on RNA isolated from seven CRC cell lines
and one non-cancerous humanCRL-1459 colon cell line, and (B) the protein analysiswas conducted on proteins isolated from these cell lines. (C) Effects of NVP-AUY922 on the viability of
HCT-15, HCT116WT, and HT-29 CRC cells. Cells were treated with NVP-AUY922 at the indicated concentrations in 10% FBS-supplemented medium for 48 and 72 h, and cell viability was
assessed by a crystal violet staining method. Bars, SD (n= 6). (D) HCT-15, HCT116WT, and HT-29 cell lines were treated with NVP-AUY922 at the indicated concentrations for 48 h. Cell
extracts were analyzed byWestern blotting with the antibodies to CDK4, caspase-3 and PARP, respectively.
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It was demonstrated that the Hsp90 inhibitors, geldanamycin and
17-AAG, induced the overexpression of survivin to enhance cell survival
and chemotherapy resistance in HT-29 cells [25]. To determinewhether
treatment with NVP-AUY922 also causes overexpression of survivin in
CRC cell lines, we treated CRC cell lines with the Hsp90 inhibitors, 17-
AAG and NVP-AUY922, respectively. As expected, the expression of
survivin was induced by 17-AAG in the three CRC cell lines (Fig. 3A,
upper panel). However, upregulation of the survivin protein just robust-
ly increased in NVP-AUY922-treated HT-29 cells (Fig. 3A, bottom
panel). This result indicated that upregulation of survivin might have
contributed to inhibiting apoptosis in NVP-AUY922-treated HT-29
cells. Silencing of survivin was then hypothesized to increase drug
sensitivity to NVP-AUY922 in HT-29 cells. To test this hypothesis, HT-
29 cells were transfected with a survivin-speciﬁc siRNA oligomer
(siSurvivin) or scrambled oligomer (control siRNA), followed by cell
viability, caspase-3 and PARP cleavage and cell cycle examinations. As
shown in Fig. 3B, survivin protein expression levels were signiﬁcantly
reduced in siSurvivin-transfected HT-29 cells. The cell-viability assayrevealed that control siRNA-transfected HT-29 cells treated with NVP-
AUY922 at the indicated concentration showed no signiﬁcant reduction
in cell viability compared to cells treated with DMSO (Fig. 3C, white
bar). However, survivin-knockdowngroups showed signiﬁcantly reduced
cell viability by ~20% in NVP-AUY922-treated HT-29 cells compared to
cells treated with DMSO (Fig. 3C, stripped bar). Moreover, Western blot
results revealed that survivin knockdown was more signiﬁcant at induc-
ing caspase-3 and PARP cleavage in NVP-AUY922-treated HT-29 cells
than control siRNA-transfected NVP-AUY922-treated HT-29 cells
(Fig. 3D). Finally, from the ﬂow cytometric analysis, we found that NVP-
AUY922-treated HT-29-siSurvivin cells showed an increased apoptotic
sub-G1 population by ~11%, compared toDMSO-treatedHT-29-siSurvivin
cells (Fig. 3E). Taken together, these results indicate that survivin plays an
important role in the sensitivity of CRC cell lines to NVP-AUY922.
3.5. BBR enhances the antiproliferative activity of NVP-AUY922 in CRC cell
lines
It is well demonstrated that the overexpression of survivin induces
resistance to various anticancer therapies such as chemotherapy and
radiation therapy in cancer cells [26,27]. Recent studies indicated that
Fig. 3. Downregulation of survivin enhanced the sensitivity of CRC cells to NVP-AUY922. (A) HCT-15, HCT116WT, and HT-29 cells were treated with various concentrations of 17-AAG or
NVP-AUY922 for 48 h. Cell lysateswere prepared after the treatment, and various proteinswere resolved by SDS-PAGE. The expression of survivinwas revealed by aWestern blot analysis.
β-Actin was used as an internal control. The relative ratio of expression is shown. (B) Expression of survivin was detected in survivin-speciﬁc siRNA-knockdown HT-29 cells byWestern
blotting. (C)HT-29 cellswere transfectedwith control siRNA and survivin-speciﬁc siRNA oligomers for 48 h and subsequently incubatedwithNVP-AUY922 at the indicated concentrations
for an additional 48 h. A cell viability assay was used to determine the viability of cells treated with various concentrations. Bars, SD (n= 6). **p b 0.01, ***p b 0.001. (D) Western blot
analysis of survivin expression, caspase-3, and PARP cleavage in HT-29 cells transfected with control siRNA and survivin-speciﬁc siRNA oligomers for 48 h and subsequently incubated
with NVP-AUY922 at the indicated concentrations for an additional 48 h.β-Actin is shown as the loading control. (E) Survivinwas silenced for 48 hwith 50 nMof speciﬁc siRNA, following
which cells were treated with NVP-AUY922 at the indicated concentrations for a further 48 h. Cell cycle distributions were analyzed by ﬂow cytometry.
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also has shown that targeting mTOR/p70S6K/survivin axis is an
attractive strategy in developing therapeutic agents against CRC cells
with chemoresistance of Hsp90 inhibitor (see Table 2 in [61]). Berberine
(BBR), an isoquinoline alkaloid traditional herbal medicine, had the
potential to inactivate the activity of p70S6K in cystic renal cells [29].
In addition, BBR was demonstrated to inhibit the proliferation of CRC
cells [30]. Thus, ﬁrst, to evaluate the cytotoxic effects of combining
NVP-AUY922 and BBR in CRC cells, we compared growth inhibition
that resulted from single or combined treatment with these two
compounds. As shown in Fig. 4A and B, the effect was greater when
the two agents were combined, even at the lowest combined dosage.
To determine whether the combination of NVP-AUY922 and BBR in
HCT-15 and HT-29 cells resulted in synergistic antiproliferative effects,
the combination index (CI) values were calculated with CompuSyn
software. CI values are summarized in Supplementary Table 3; CI values
were b1, indicating that a synergistic antiproliferative effects existbetween NVP-AUY922 and BBR in HCT-15 and HT-29 cells. In view of
the above-mentioned growth-inhibitory effects, we were interested in
understanding the synergistic effect of NVP-AUY922 and BBR in causing
CRC cell growth arrest and death. We next examined the effects of the
combination of NVP-AUY922 and BBR on apoptosis and the cell cycle
distribution in HCT-15 and HT-29 cells. When simultaneously com-
bined, BBR enhanced NVP-AUY922-induced apoptosis and G2/M arrest
in HCT-15 cells (Supplementary Fig. 4), but only slight changed the
sub-G1 and G2/M phases of HT-29 cells (Supplementary Fig. 5). In
addition, in HCT-15 cells, the combination of NVP-AUY922 and BBR
also caused an increase of cells in the S phase and a corresponding
decrease of cells in the G1 phase (Supplementary Fig. 4); this prevented
cells from entering the G2 phase of the cell cycle. In the HT-29 cell line,
there was a decrease of cells in the S phase in NVP-AUY922 and BBR
combination groups which indicated cell growth inhibition (Supple-
mentary Fig. 5). To further characterize the effects of the combination
of NVP-AUY922 and BBR, we used Western blotting to analyze
Fig. 4. Berberine (BBR) increased the antitumor activity of NVP-AUY922 in CRC cells. A crystal violet staining assay revealed growth inhibition by NVP-AUY922, BBR, or both drugs in
combination in HCT-15 (A) and HT-29 cells (B) for 72 h. Bars, SD (n= 6). *p b 0.05, **p b 0.01, ***p b 0.001. (C) Western blot revealing decreased expressions of cell cycle regulators
and increased induction of proapoptotic proteins after combined exposure of HCT-15 cells to NVP-AUY922 and BBR at the indicated concentrations for 72 h. (D) Western blot revealing
decreased expression of a cell cycle regulator, but no induction of proapoptotic proteins after the combined exposure of HT-29 cells to NVP-AUY922 and BBR at the indicated concentra-
tions for 72 h.
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treating HCT-15 or HT-29 CRC cells with NVP-AUY922 and BBR. We
observed that combination treatment with NVP-AUY922 and BBR
signiﬁcantly decreases survivin expression in two CRC cell lines
(Fig. 4C and D). In addition, exposure to NVP-AUY922 and BBR
signiﬁcantly decreased cell-cycle progression and slightly increased
apoptosis, which was assessed by a decrease in expressions of cell-
cycle regulatory proteins (cyclin D1 and CDK4) and induction of
caspase-3 and PARP cleavage in HCT-15 cells (Fig. 4C). Surprisingly,
the effect of combined treatment with NVP-AUY922 and BBR
signiﬁcantly decreased cell cycle progression in HT-29 cells by
decreasing expressions of cyclin D1 and CDK4 (Fig. 4D). In summary,
these data indicate that the antiproliferative effect of the combina-
tion of NVP-AUY922 and BBR on CRC cell lines was by simultaneously
inducing apoptosis and cell cycle arrest at the S phase in HCT-15
cells, but inhibiting the proliferation rate by inhibiting the S phase
in HT-29 cells.
3.6. Treatment of CRC lineswithNVP-AUY922 plus BBR results in distinct al-
terations in phospho-kinase activity
To determine the potential molecular mechanisms by which BBR
treatment can sensitize CRC cells to NVP-AUY922 and cause CRC cell
growth arrest or death, the HCT-15 and HT-29 cell lines were treated
with the DMSO control, NVP-AUY922, or NVP-AUY922 plus BBR, and a
human phospho-kinase array was performed which contained 42kinases and two related total proteins. As shown in Fig. 5A, the
phospho-kinase array analysis of HCT-15 cells identiﬁed several path-
ways which were signiﬁcantly downregulated by the combination of
NVP-AUY922 and BBR, compared to the DMSO treatment group. These
pathways included the mammalian target of rapamycin (mTOR)/
p70S6 kinase pathway, Akt/glycogen synthase kinase-3 α/β (GSK3α/
β) pathway and members of the mitogen-activated protein kinase
(MAPK) signaling pathway (c-Jun N-terminal kinases (JNKs)). Howev-
er, in HT-29 cells, the above-mentioned kinases did not appear to be
downregulated by the combination of NVP-AUY922 and BBR (Fig. 5B).
To conﬁrm this observation, results from antibody array studies were
conﬁrmed by Western blots. Protein lysates from the DMSO control-,
NVP-AUY922-, or NVP-AUY922 plus BBR-treated HCT-15 and HT-29
cells were analyzed using the antibodies described above. As shown in
Fig. 5C, treatment of HCT-15 cells with the combination of NVP-
AUY922 and BBR resulted in marked reductions of phosphorylated
mTOR at Ser2448, phosphorylated p70S6K at Thr389, phosphorylated
Akt at Thr308 and Ser473, and phosphorylated GSK3β at Ser9. In
contrast, there were no signiﬁcant changes in the phosphorylation
levels of these kinases in HT-29 cells treated with the combination of
NVP-AUY922 and BBR (Fig. 5D), except for the phosphorylation level
of mTOR. Collectively, on the basis of the above results, a broad
spectrum of kinases involved in regulating cell growth arrest and
death were signiﬁcantly downregulated by the combination of NVP-
AUY922 and BBR-treated NVP-AUY922-sensitive HCT-15 cells, not in
NVP-AUY922-insensitive HT-29 cells.
Fig. 5. Human phospho-kinase array analysis in response to combined NVP-AUY922 and BBR treatment. (A) mTOR/p70S6 kinase pathway, Akt/GSK3α/β pathway, and members of the
MAPK signaling pathway, JNKs, were signiﬁcantly downregulated by the combination of NVP-AUY922 and BBR in HCT-15 cells. Each phospho-kinase array displays duplicate signal
spots for each gene. Comparison of the pixel densities of phospho-kinase array signals. The dot densitywas scanned from the scannedX-ray ﬁlm, and imageswere analyzed and quantiﬁed
using image analysis software (NIH-Image J). *p b 0.05, **p b 0.01, ***p b 0.001. (B) mTOR/p70S6 kinase pathway, Akt/GSK3α/β pathway, and JNK signals were not signiﬁcantly downreg-
ulated by the combination of NVP-AUY922and BBR inHT-29 cells. HCT-15 (C) andHT-29 cells (D)were either treatedwithDMSO, or exposed toNVP-AUY922 alone or combinedwith BBR
for 48 h. Equal amounts of cell lysates were analyzed for mTOR, p70S6, Akt, GSK3β and JNK phosphorylation by a Western blot analysis.
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AUY922-insensitive HT-29 cells strikingly induced miR-296-5p-mediated
suppression of Pin1–β-catenin–cyclin D1 signaling
Previous study showed that peptidyl-prolyl isomerase, Pin1, is a
cochaperone in a scaffolding Hsp90 complex which can be destabilized
byHsp90 inhibitors [31]. Moreover, Pin1 is the upstream regulator of β-
catenin [32], and Pin1–β-catenin signalingwas shown to regulate cyclin
D1 expression in human breast, liver, and colon cancers when Pin1 wasoverexpressed [33–36]. In the present study, we found that the
combination of NVP-AUY922 and BBR signiﬁcantly downregulated β-
catenin expression levels compared to DMSO-treated HT-29 cells from
our human phospho-kinase array results (Fig. 6A). To conﬁrm the
phospho-kinase array results, we investigated the effect of NVP-
AUY922 or NVP-AUY922 plus BBR on the expressions of Pin1, β-
catenin, and cyclin D1 by a Western blot analysis. Signiﬁcant decreases
in the expressions of these three proteins were observed after NVP-
AUY922 plus BBR treatment in HT-29 cells (Fig. 6B, right panel).
Fig. 6.miR-296-5p–Pin1–β-catenin–cyclin D1 signaling is involved in the combined NVP-AUY922 and BBR-mediated cell growth arrest of HT-29 cells. (A) Comparison of pixel densities of
β-catenin signals in the HCT-15 and HT-29 cell lines. (B) Western blot analysis of protein expressions of Pin1, β-catenin, and cyclin D1 in NAV-AUY922 alone or combined NVP-AUY922
and BBR-treated of HCT-15 and HT-29 cell lines. The relative ratio of expression is shown. (C) The miR-296-5p expression in HCT-15 and HT-29 with or without NVP-AUY922 alone or
combined with BBR treatment for 24 h was analyzed by quantitative RT-PCR. Signiﬁcant up-regulation of miR-296-5p was observed in combination of NVP-AUY922 and BBR-treated
of HT-29 cells. **p b 0.01, ***p b 0.001. (D) Pin1–β-catenin–cyclin D1 signaling was suppressed by NVP-AUY922 alone or NVP-AUY922 plus BBR-treated of GFP-transfected HT-29 cells,
not in HCT-15 cells. The inhibition of Pin1–β-catenin–cyclin D1 signaling was attenuated by transfection of Pin1-expressing plasmid in the presence of NVP-AUY922 alone or NVP-
AUY922 plus BBR of HT-29 cells. (E) Suppressed cell proliferation rate by NVP-AUY922 plus BBR was rescued by ectopic Pin1 expression of HT-29 cells by MTT assay. *p b 0.05,
**p b 0.01, ***p b 0.001.
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reduced by about 60–70% of these three proteins in NVP-AUY922 plus
BBR-treated HT-29 cells (Fig. 6B, right panel). In contrast, there was
no signiﬁcant change in the expression level of Pin1–β-catenin–cyclin
D1 signaling in HCT-15 cells treated with the combination of NVP-
AUY922 and BBR (Fig. 6B, left panel). More recently, we have reported
that microRNA-296-5p (miR-296-5p) was identiﬁed to play a tumor-
suppressive role by targeting the 3′-UTR of Pin1 mRNA of prostate
cancer [37]. In addition, miR-296-5p was recently found to be progres-
sively lost during tumor progression in various cancers, including CRC
[38–40]. To understand the correlation between miR-296-5p and Pin1
in CRC, we ﬁrst analyzed the expression levels of Pin1 protein and
miR-296-5p in CRC cell lines by Western blot and quantitative RT-PCR
analysis. As shown in Supplementary Fig. 6A, the Pin1 protein was
highly expressed in ﬁve CRC cell lines compared with non-cancerous
human colon cells CRL-1459. The miR-296-5p expression was then
examined in these cell lines, showing that miR-296-5p were clearly
downregulated in ﬁve CRC cell lines compared with CRL-1459 cells
(Supplementary Fig. 6B). Across all six cell lines tested, we found an
inverse correlation between Pin1 protein levels and miR-296-5p
(Pearson correlation coefﬁcient [r] =−0.91); however, there was no
association between Pin1-mRNA and miR-296-5p (Supplementary
Fig. 6C and B, Pearson correlation coefﬁcient [r] = 0.48). These results
are consistent with our previous study showing that miR-296-5p
playing a tumor-suppressive role by targeting Pin1. We further investi-
gated the effect of combination of NVP-AUY922 and BBR onmiR-296-5p
expression. As shown in Fig. 6C, we found that treatment of HT-29 cells
with the combination of NVP-AUY922 and BBR resulted in markedinduction in miR-296-5p expression. Although the expression of miR-
296-5p was also induced in NVP-AUY922 alone-treated of HCT-15 and
HT-29 cell lines, the induction level ofmiR-296-5pwas not high enough
to affect the Pin1–β-catenin–cyclin D1 signaling in this two cell lines.
Taken together, these results indicated that BBR can enhance the
potency of NVP-AUY922 in NVP-AUY922-insensitive HT-29 cells
through induced miR-296-5p-mediated suppression of Pin1–β-caten-
in–cyclin D1 signaling. Next, to further investigate whether over-
expression of Pin1 could abolish drugs trigger cell growth inhibition,
we performed the rescue experiment by introducing Pin1-expressing
plasmid (pEGFP-Pin1) or empty vector in the presence of NVP-
AUY922 alone or NVP-AUY922 plus BBR in HCT-15 and HT-29 cells. As
shown in Fig. 6D, ectopic GFP-Pin1 expression can abolish NVP-
AUY922 plus BBR-mediated induction of miR-296-5p-regulated
suppression of the expression of Pin1, β-catenin, and cyclin D1 proteins
in HT-29 cells (Fig. 6D, right panel). As expected, there were no signiﬁ-
cant changes in the amounts of Pin1, β-catenin, and cyclin D1 proteins
in GFP-Pin1-transfected HCT-15 cells in the presence of NVP-AUY922
alone or NVP-AUY922 plus BBR (Fig. 6D, left panel). Moreover, anti-
growth effect of NVP-AUY922 plus BBR was signiﬁcantly attenuated
by ectopic GFP-Pin1 expression of HT-29 cells (Fig. 6E, right panel,
lanes 1 and 3of GFP group versus lanes 1 and 3of GFP-Pin1 group).
However, this phenomenon cannot be observed in HCT-15 cells
(Fig. 6E, left panel). This result clariﬁes that NVP-AUY922 plus BBR-
mediated inhibition cell growth of HT-29 cells can be through miR-
296-5p-mediated suppression of Pin1–β-catenin–cyclin D1 signaling,
and that overexpression of Pin1 can abolish pre-miR-296-5p-
mediated growth suppression of HT-29 cells. Collectively, these results
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296-5p expression and function in NVP-AUY922-insensitive HT-29
cells, as shown by a reduction of Pin1–β-catenin–cyclin D1 signaling
pathway, an important oncogenic pathway in CRC.
3.8. Hsp90, Hsp90 client proteins and co-chaperone expression in CRC
clinical tissues
To understand whether the expression of Hsp90, Hsp90 client
proteins and co-chaperone in cell line models were correlated with
CRC clinical tissues, the protein expression levels of Hsp90, CDK4,
survivin and Pin1 were determined by IHC in 192 specimens of CRC
tissues. The association of several clinicopathologic factors with the
proteins mentioned above were illustrated in Supplementary Tables 4
to 7. As shown in Supplementary Table 4, the level of expression of
Hsp90 in patients with nodal metastasis was signiﬁcantly higher than
in those with no metastasis (53.2% vs. 27.7%, p b 0.0001). In addition,
patients with advanced-stage (stages III and IV) disease had higher
Hsp90 expression than patientswith early-stage (stages I and II) disease
(49.6% vs. 30.7%, p= 0.011). This result is consistent with the previous
ﬁnding to indicate that the expression of Hsp90 is elevated in progres-
sion of CRC [41]. Furthermore, it has been reported that therapeutic
selectivity of Hsp90 inhibitors is due to the presence of highly expressed
of Hsp90 in malignant cells [42,43]. Thus, these results offer the
evidence in support of our hypothesis that Hsp90 inhibitors represent
potential candidates for treating CRC. The association of clinicopatho-
logic factors with Hsp90 client proteins (CDK4 and survivin) indicated
that high CDK4 or survivin expressionwas associatedwith tumor stages
(p= 0.028 for CDK4, p= 0.008 for survivin) (Supplementary Tables 5
and 6). In addition, we found that Pin1 was highly expressed in over
50% of CRC tissues, however, no signiﬁcant association was found
between Pin1 expression and clinicopathologic factors (Supplementary
Table 7). We ﬁnally analyzed the correlation of Hsp90, CDK4, survivin
and Pin1 expression in the tumor tissue of the CRC patients. As shown
in Table 2, the expression of CDK4 and Pin1 was signiﬁcantly positively
correlated with levels of Hsp90 (p = 0.030 for CDK4; p = 0.049 for
Pin1). However, no signiﬁcant correlation was found between survivin
and Hsp90 expression in the tumor tissues of the CRC patients (p =
0.658). Collectively, these results reﬂect our in vitro results to indicate
that simultaneous inhibition of Hsp90-regulated signaling and survivin
can enhance the potency of Hsp90 inhibitor in CRC cells.
4. Discussion
Gene expression data have traditionally been used to identify
speciﬁc genes or pathways associatedwith a disease or drug application
[44]. More recently, ﬁnding ‘connections’ between gene–disease or
disease–drug pairs using the CMap [13], which aimed to identify if
drugs used for one disease can be applied to another, can beneﬁt from
this new approach [15,45]. In this study, we demonstrated the
combined approach of microarray gene expression of CRC patientsTable 2
The correlation of Hsp90, CDK4, survivin, and Pin1 expression in tumor tissues of CRC.
Hsp90
Low, n (%)
(n = 111)
High, n (%)
(n = 81) p Value
CDK4 0.030
Low (n = 128) 81 (63.3) 47 (36.7)
High (n = 64) 30 (46.9) 34 (53.1)
Survivin 0.658
Low (n = 109) 65 (59.6) 44 (40.4)
High (n = 83) 46 (55.4) 37 (44.6)
Pin1 0.049
Low (n = 87) 57 (65.5) 30 (34.5)
High (n = 105) 54 (51.4) 51 (48.6)and CMap data mining to discover the mechanisms of action for the
second generation Hsp90 inhibitor, NVP-AUY-922, in CRC cells. There
are several lines of evidence that support this conclusion which are
listed below. First, NVP-AUY922 has signiﬁcant proapoptotic and anti-
proliferative effects in CRC cell lines in vitro. Second, NVP-AUY922-
induced drug insensitivity can be abolished by gene-speciﬁc or
pharmaceutical approaches to inhibit survivin expression. Third, the
combination treatment of NVP-AUY922-sensitive cells with NVP-
AUY922 and BBR signiﬁcantly downregulated the activities of a broad
spectrum of kinases involved in regulating cell growth arrest and
death. Fourth, combined treatment of NVP-AUY922-insensitive cells
with NVP-AUY922 and BBR caused cell growth arrest through inhibiting
CDK4 expression and miR-296-5p-mediated suppression of Pin1–β-ca-
tenin–cyclin D1 signaling pathway. Collectively, this study is the ﬁrst to
report that a combination of NVP-AUY922 and BBR has the potential to
treat CRC by a gene expression-based chemical genomics approach, and
the regulatorymechanisms of the combination of NVP-AUY922 and BBR
were identiﬁed and are summarized in Supplementary Fig. 7.
In the present study, we compared gene expression proﬁles of CRC
patients and those of normal colon control patients with no colorectal
neoplasmusing the CMap. The CMap analysis is based on the expression
statuses of hundreds of genes, and not of a single gene. This method has
not been applied to CRC patients until now. The use of this method
allows identiﬁcation of some candidate drugs for CRC. Tanespimycin
and LY-294002were the top two compounds with the highest negative
connectivity scores in our CMap results (Table 1). Tanespimycin is an
Hsp90 inhibitor with a less-toxic analogue of geldanamycin, and
LY294002 was an early PI3 kinase inhibitor. Hsp90 and PI3 kinase are
key proteins and drug targets withmajor roles in controlling cell surviv-
al, cell growth, and apoptosis by modulating the activities of a number
of pathways [46,47]. Moreover, Hsp90-client and PI3 kinase-regulated
pathways are often activated in CRC [48]. Hence, targeting Hsp90 or
PI3 kinase with potent selective inhibitors can result in cancer cell
growth inhibition and induction of cancer cell apoptosis. Thus, analyses
of gene expression proﬁles of CRC patients in this study suggested that
Hsp90 could be an effective therapeutic drug target.
Currently, more than 13 small molecule inhibitors of Hsp90 are at
various stages of preclinical and clinical development [49]. Tanespimycin
was the ﬁrst Hsp90 inhibitor to enter clinical trials [50]. It showed antitu-
mor activity at non-toxic doses in several human tumor xenograft
models and has completed phase II clinical trials in a number of cancers
[51–55]. However, it was demonstrated that the Hsp90 inhibitors,
geldanamycin and tanespimycin, induced the overexpression of survivin
in lung, nasopharyngeal, and colon cancer cell lines and subsequently
enhanced cancer cells' anti-drug ability [25]. Moreover, the survivin
protein was strongly positive in the cytoplasm of CRC cells of specimens
[56]. Our study demonstrated for theﬁrst time that targeting Hsp90with
the second generation Hsp90 inhibitor, NVP-AUY922, caused signiﬁcant
upregulation of survivin in HT-29 cells. Speciﬁc inhibition of survivin
expression in HT-29 cells by siSurvivin enhanced NVP-AUY922-
induced caspase-3-dependent apoptosis. This result implied that the
combination of a survivin inhibitor and an Hsp90 inhibitor can provide
therapeutic beneﬁts to patients of CRCwith resistance toHsp90 inhibitor
treatment. It has been demonstrated that BBR has potency to inhibit
survivin of CRC cells [57]. In addition, BBR is one of the most important
alkaloids and is widely used as an antibacterial and antimalarial drug.
In addition, it was also demonstrated that BBR produces no organ
toxicity [58]. In the present study, we found that the combination of
NVP-AUY922 and BBR signiﬁcantly inhibited HT-29 cell growth due to
cell growth arrest but did not signiﬁcantly induce activation of apoptosis.
Themolecular mechanism of the combination of NVP-AUY922 and BBR-
triggered HT-29 cell growth arrest was through inhibition of CDK4
expression and induction of miR-296-5p-mediated suppression of the
Pin1–β-catenin–cyclin D1 signaling pathway. It was demonstrated that
Pin1 binds the phosphorylated Thr34-Pro35 motif of survivin and
functions as a positive regulator of the antiapoptotic function of surviving
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expressions of survivin (Fig. 4D) and Pin1 proteins (Fig. 6B) were
found after NVP-AUY922 plus BBR treatment of HT-29 cells, but the
downregulation of survivin and Pin1 proteins was not found to enhance
apoptosis in drug-treated HT-29 cells. Thus, such expression interactions
between survivin and Pin1 in inhibiting apoptosis in CRC cells may
account for the chemoresistance of tumors with survivin and Pin1
overexpression.
In conclusion, both Hsp90 and survivin are regarded as oncogenic
proteins, and both have been reported to be drug targets. However,
existing survivin targeting strategies have only yielded partial positive
responses in clinical trials [60]. Our ﬁndings provide a model in which
BBR can enhances the antiproliferative activity of NVP-AUY922 in CRC
cell lines through inhibition of multiple oncogenic signaling pathways.
Moreover, combination treatment with NVP-AUY922 and BBR of CRC
cells can abolish NVP-AUY922-induced overexpression of survivin in
CRC cells. Thus, dual inhibition of Hsp90 and survivin may enhance the
potency of Hsp90 inhibitors and overcome drug resistance in cancer cells.
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